1 |
Taylor AE et al. Determinants of abnormal gonadotropin secretion in clinical defined women woth polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism. 1997;82 :2248-56.
DOI
ScienceOn
|
2 |
Azziz R et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome:an Androgen Excess Society guideline. Journal of Clinical Endocrinology & Metabolism. 2006;91:4237-45.
DOI
ScienceOn
|
3 |
Hahn S et al. Clinical and biochemical characterization of women with polycystic ovary syndrome in North Rhine- Westphalia. Hormone and Metabolic Research. 2005;37:438-44.
DOI
ScienceOn
|
4 |
Lala HE et al. An increased intraovarian synthesis of nerve growth factor and its low affinity receptor is a principal component of steroid-induced polycystic ovary in the rat. Endocrinology. 2000 ;141:1059-72.
DOI
ScienceOn
|
5 |
Schulster A, Farookhi R, Brawer JR. Polycystic ovarian condition in estradiol valerate -treated rat: Spontaneous changes in characteristic endocrine features. Biology of Reproduction. 1984;31:587-93.
DOI
ScienceOn
|
6 |
Conway GS, Honour JW, Jacobs HS. Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients. Clinical Endocrinology. 1989;30:459-70.
DOI
|
7 |
남은정 등. 定經湯이 estradiol valerate로 유발된 흰쥐의 다낭성 난소에 미치는 영향. 대한한방부인과학회지. 2007;20(1):99-113.
과학기술학회마을
|
8 |
Manni L et al. Effects of exrecise on ovarian morphology and expression of nerve growth factor and -and -adrenergic receptors in rats with steroid-induced polycystic ovaries. Journal of Neuroendocrinology. 2005; 17:846-58.
|
9 |
양승정 등. 蒼附導痰湯이 estradiol valerate로 유발된 백서의 다낭성 난소에 미치 는 影響. 대한한방부인과학회지. 2002;15(2):1-11.
과학기술학회마을
|
10 |
Arroyo A et al. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity. Journal of Clinical Endocrinology & Metabolism. 1997;82:3728-33.
DOI
ScienceOn
|
11 |
Anttila L et al. Clinical features and circulating gonadotropin, insulin, and androgen interactions in women with polycystic ovarian disease. Fertil and Steril. 1991;55:1057-61.
DOI
|
12 |
Lergo RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. The American journal of medicine. 2001;111:607-13.
DOI
ScienceOn
|
13 |
Santbrink EJ, Hop WC, Fauser BC. Classification of normogonadotropic infertility:polycystic ovaries diagnosed by ultrasound versus endocrine characteristics of polycystic ovary syndrome. Fertil and Steril. 1997;67:452-8.
DOI
ScienceOn
|
14 |
Lergo RS et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. Journal of Clinical Endocrinology & Metabolism. 1999;84:165-9.
DOI
ScienceOn
|
15 |
Rebar R et al. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism. 1976;57:1320-9.
|
16 |
Aguado LI, Petrovic SL, Ojeda SR. Ovarian -adrenergic receptors during the onset of puberty: characterization, distribution, and coupling to steroidogenic responses. Endocrinology. 1982;110(4):1124-32.
DOI
ScienceOn
|
17 |
Dyer CA, Erickson GF. Norepinephrine amplifies human chorionic gonadotropin -stimulated androgen biosynthesis by ovarian theca-interstitial cells. Endocrinology. 1985;116(4):1645-52.
DOI
ScienceOn
|
18 |
Dissen GA et al. Intraovarian excess of nerve growth factor increases androgen secretion and disrupts estrous cyclicity in the rat. Endocrinology. 2000;141(3):1073-81.
DOI
ScienceOn
|
19 |
DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil and Steril. 2005;83:1454-1460.
DOI
ScienceOn
|
20 |
Lergo RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism. 1998;93:2694-8.
|
21 |
허 준. 동의보감. 서울:법인문화사. 2002;290, 291, 362.
|
22 |
Levin N et al. Decreased food intake does not completely account for adiposity reduction after ob protein infusion. Proceedings of the National Academy of Sciences of the United States of America. 1996;93(4):1726-30.
DOI
ScienceOn
|
23 |
Stener VE. Acupuncture in reproductive medicine: Overview and summary of recent studies. International Congress Series. 2002;1238:149-56.
DOI
ScienceOn
|
24 |
Carmina E et al. Difference in body weight between American and Italian women with polycystic ovary syndrome :influence of the diet. Human Reproduction. 2003;18:2289-93.
DOI
ScienceOn
|
25 |
Levi MR. The nerve growth factor 35 years later. Science. 1987;237:1154-62.
DOI
|
26 |
The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and ling term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41-7.
DOI
ScienceOn
|
27 |
Azziz R et al. Androgen excess in women: experience with over 1000 consecutive patients. Journal of Clinical Endocrinology & Metabolism. 2004;89:453-62.
DOI
ScienceOn
|
28 |
Anderson E, Lee GY, O'Brien K. Polycystic ovarian condition in the dehydroepiandrosterone-treated rat model: Hyperandrogenism and the resumption of meiosis are major initial events associated with cystogenesis of antral follicles. Reproductive Biology. 1998;249(1):44-53.
|
29 |
Halaas JL et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 1995;269(5223) :543-6.
DOI
|
30 |
전국한의과대학본초학교실. 본초학. 서울:영림사. 2000:290, 303, 348, 349, 353, 355, 379, 409, 417, 448, 541.
|
31 |
Barb CR et al. Inhibition of ovulation and LH secretion in the gilt after treatment with ACTH or hydrocortisone. Journal of Reproduction and Fertility. 1982;64(1):85-92.
DOI
ScienceOn
|
32 |
Conway GS et al. Effects of Luteinizing Hormone, Insulin, Insulin-like Growth Factor-I and Insulin-like Growth Factor Small Binding Protein 1 in the Polycystic Ovary Syndrome. Clinical Endocrinology. 1990;33:596-603.
|
33 |
Stener VE et al. Effects of electro -acupuncture on corticotropin-releasing factor in rats with experimentallyinduced polycystic ovaries. Neuropeptides. 2001;35(5&6):227-31.
DOI
ScienceOn
|
34 |
김근우, 구병수. 항(抗) Stress 실험에관한 비교 연구. 동의신경정신과학회지. 1997;8(1):111-25.
|
35 |
한의부인과학 편찬위원회. 한의부인과학(上). 서울:정담. 2002:126, 410.
|
36 |
Stener VE et al. Effects of eletro -acupuncture on nerve growth factor and ovarian morphology in rats with experimentally induced polycystic ovaries. Biology of Reproduction. 2000;63(5):1497-503.
DOI
ScienceOn
|
37 |
김희주, 김윤상, 임은미. 蒼附六君湯이 estradiol valerate로 유발된 흰쥐의 다낭성 난소에 미치는 영향. 대한한방부인과학회지. 2008;21(2):1-16.
과학기술학회마을
|
38 |
윤소영, 강명자. 다낭성 난소증후군환자의 한방 치료에 대한 임상적 고 찰. 대한한방부인과학회지. 2000;13(2):437-51.
|
39 |
이연경 등. 歸脾湯이 estradiol valerate로 유발된 흰쥐의 다낭성 난소에 미치는 영향. 대한한방부인과학회지. 2008;21(3):60-74.
과학기술학회마을
|
40 |
유영기 등. 腎氣丸合蒼附導痰湯이 estradiolvalerate로 유발된 흰쥐의 다낭성 난소에 미치는 영향. 대한한방부인과학회지. 2007;20(1):84-98.
과학기술학회마을
|
41 |
김세련, 김종욱. 고인슐린 혈증과 다낭성난소증후군의 병태 생리. 관동의대학술지. 2005;9(1):89-98.
|
42 |
Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome :towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, editors. Polycystic ovary syndrome. 3rd ed. Boston. Blackwell Scientific Publication. 1992;377-84.
|
43 |
The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and ling term health risks related to polycystic ovary syndrome. Fertil and Steril. 2004;81:19-25.
|
44 |
김 탁. 다낭성 난소 증후군의 최신 지견. 대한산부인과학회 연수강좌. 2002;31 :38-44.
|
45 |
Stener VE et al. Rats with steroid -induced polycystic ovaries develop hypertension and increased sympathetic nervous system activity. Reproductive Biology and Endocrinology. 2005;3:44.
DOI
ScienceOn
|
46 |
Polson DW et al. Polycystic ovaries-a common finding in normal women. The Lancet. 1988;1:870-2.
|
47 |
Balen AH et al. Ultrasound assessment of the polycystic ovary:international consensus definitions. Human Reproduction Update. 2003;9:505-14.
DOI
ScienceOn
|
48 |
민응기. 다낭성 난소 증후군. 대한산부인과학회지. 2008;51(8):805-19.
|
49 |
吳桂芳, 李祥云. 中醫學治療多囊卵巢 綜合症硏究槪況. 河南中醫. 1994;14(2) :123-5.
|
50 |
Baillargeon JP. Use of insulin sensitizers in polycystic ovarian syndrome. Current Opinion in Investigational Drugs. 2005;6:1012-22.
|
51 |
金維新. 不孕症的診斷與中醫治療. 北京:科學出版社. 1992:172-7.
|
52 |
萬全. 萬氏婦人科. 湖北省:湖北人民出版社. 1983:9-10.
|
53 |
이혜진, 성연아. 다낭난소증후군의 진단과 치료. 대한내분비학회지. 2007;22(4):252-6.
|
54 |
Brawer JR, Munoz M, Farookhi R. Development of the polycystic ovarian condition(PCO) in the estradiol valerate -treated rat. Biology of Reproduction. 1986;35:647-55.
DOI
ScienceOn
|
55 |
Brawer JR et al. Effects of a single injection of estradiol valerate on the hypothalamic arcuate nucleus and on reproductive function in the female rat. Endocrinology. 1978;103:501-12.
DOI
ScienceOn
|
56 |
대한산부인과학회 교과서편찬위원회.부인과학. 서울:고려의학. 2007:63, 362.
|
57 |
김동일, 윤종원, 이태균. 다낭성 난소증후군에 관한 문헌적 고찰. 대한한방부인과학회지. 1997;10(1):73-91.
|
58 |
김정훈. 다낭성난소증후군 치료의 최신지견. 대한산부인과학회지. 2005;48(8) :1851-69.
|
59 |
Krysiak R et al. Update on the management of polycystic ovary syndrome. Pharmacological Reports. 2006;58(5):614-25.
|